Levacetylleucine

Levacetylleucine

SCHEMBL714003

CC(=O)N[C@H](CC(C)C)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 1.00
MEN1 O00255 1/20 0.64
LMNA P02545 1/20 0.64
KMT2A Q03164 1/20 0.64
MAPT P10636 2/20 0.60
KDM4E B2RXH2 1/20 0.59
THRB P10828 1/20 0.59
ALOX15 P16050 1/20 0.59
NFKB1 P19838 1/20 0.59
PTGS2 P35354 1/20 0.59
THPO P40225 1/20 0.59
RECQL P46063 1/20 0.59
BLM P54132 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
FOLH1 Q04609 9/20 0.56
LAP3 P28838 3/20 0.53
NAALAD2 Q9Y3Q0 2/20 0.52
PLA2G2A P14555 2/20 0.50
PLA2G5 P39877 2/20 0.50
GRN P28799 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Levacetylleucine SCHEMBL9438432 1.00 ALDH1A1 (1.00) ALDH1A1MEN1LMNAKMT2AMAPT
Levacetylleucine SCHEMBL282372 1.00 ALDH1A1 (1.00) ALDH1A1MEN1LMNAKMT2AMAPT
Acetylleucine SCHEMBL282371 1.00 ALDH1A1 (1.00) ALDH1A1MEN1LMNAKMT2AMAPT
Levacetylleucine SCHEMBL5527234 0.98 ALDH1A1 (0.96) ALDH1A1MEN1LMNAKMT2AMAPT
Levacetylleucine SCHEMBL18954336 0.98 ALDH1A1 (0.96) ALDH1A1MEN1LMNAKMT2AMAPT
Levacetylleucine SCHEMBL7923132 0.98 ALDH1A1 (0.96) ALDH1A1MEN1LMNAKMT2AMAPT
Levacetylleucine SCHEMBL5532016 0.98 ALDH1A1 (0.96) ALDH1A1MEN1LMNAKMT2AMAPT
Acetylleucine SCHEMBL25408262 0.94 ALDH1A1 (0.88) ALDH1A1MEN1LMNAKMT2AMAPT
Levacetylleucine SCHEMBL6863674 0.92 ALDH1A1 (0.85) ALDH1A1MEN1LMNAKMT2AMAPT
SCHEMBL17948650 0.92 ALDH1A1 (0.85) ALDH1A1MEN1LMNAKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 636 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3375771-B1 METHOD FOR PRODUCING LACOSAMIDE AND INTERMEDIATE THEREOF UBE CORP (JP) 2025-11-26 EP claimed
US-12441774-B2 Molecular guide system peptides and uses thereof SRI INTERNATIONAL (US) 2025-10-14 US claimed
US-20250312302-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEVELOPMENTAL DISORDERS SYNGAP RES FUND (US) 2025-10-09 US claimed
EP-4608828-A1 IMPROVED PROCESSES FOR PREPARING DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVES Yuhan Corporation (KR) 2025-09-03 EP claimed
US-12403111-B2 Compositions and methods for treating neurodevelopmental disorders SynGAP Research Fund (US) 2025-09-02 US claimed
US-20250270187-A1 MOLECULAR EDITING OF MULTIPLE C-H BONDS LEVERAGING RECOGNITION OF DISTANCE, GEOMETRY AND CHIRALITY THE SCRIPPS RESEARCH INSTITUTE 2025-08-28 US claimed
US-20250248959-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEVELOPMENTAL DISORDERS UNIVERSITY OF UTAH RESEARCH FOUNDATION 2025-08-07 US claimed
CN-119923397-A Improved process for preparing dimethyl-2, 3-dihydro-1H-indene derivatives 柳韩洋行 2025-05-02 CN claimed
US-20250100999-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2025-03-27 US claimed
CN-114262704-B Immobilized carrier, D-acetylleucine deacetylation immobilized enzyme and preparation method 亿利耐雀生物科技有限公司 2024-11-01 CN claimed
US-6514742-B1 Given physico-chemical properties; from fungi; use to deacetylate N-acetyl-D-amino acids DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2003-02-04 US claimed
US-20020151035-A1 D-aminoacylase and gene encoding the same DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2002-10-17 US claimed
US-20020090713-A1 Enzymatic polypeptide for generating preferential amino acids DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2002-07-11 US claimed
EP-1178114-A2 Heat-stable d-aminoacylase Daicel Chemical Industries, Ltd. (JP) 2002-02-06 EP claimed
EP-1120465-A1 D-Aminoacylase and gene encoding the same Daicel Chemical Industries, Ltd. (JP) 2001-08-01 EP claimed
US-6030823-A FOR INDUSTRIAL PRODUCTION OF D-AMINO ACIDS FROM N-ACETYL-D-AMINO ACIDS DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2000-02-29 US claimed
EP-0976828-A1 Fungal D-aminoacylases and method for producing D-amino acids DAICEL CHEMICAL INDUSTRIES, Ltd. (JP) 2000-02-02 EP claimed
EP-0950706-A2 D-aminoacylase DAICEL CHEMICAL INDUSTRIES, Ltd. (JP) 1999-10-20 EP claimed
US-5916774-A PRODUCES D-AMINO ACIDS FROM CORRESPONDING N-ACETYL-D-AMINO ACIDS; ACTIVITY PROMOTED BY COBALT AND CALCIUM IONS BUT INHIBITED BY COPPER, MERCURY AND ZINC IONS DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1999-06-29 US claimed
EP-0896057-A2 D-aminoacylase DAICEL CHEMICAL INDUSTRIES, Ltd. (JP) 1999-02-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250248959-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEVELOPMENTAL DISORDERS SLC1A2, CHAT, BDNF ALDH1A1 629/4885MEN1 4188/4885LMNA 2838/4885
US-20250312302-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEVELOPMENTAL DISORDERS SLC1A2, CHAT, BDNF ALDH1A1 629/4885MEN1 4188/4885LMNA 2838/4885
US-12403111-B2 Compositions and methods for treating neurodevelopmental disorders SLC1A2, CHAT, BDNF ALDH1A1 629/4885MEN1 4188/4885LMNA 2838/4885
US-20020090713-A1 Enzymatic polypeptide for generating preferential amino acids DNPEP, NAALAD2, DAO ALDH1A1 663/4885MEN1 2863/4885LMNA 3299/4885
US-20250270187-A1 MOLECULAR EDITING OF MULTIPLE C-H BONDS LEVERAGING RECOGNITION OF DISTANCE, GEOMETRY AND CHIRALITY CYCS, CYC1, CDA ALDH1A1 222/4885MEN1 4381/4885LMNA 2697/4885
US-20250100999-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS CYP11A1, CYP11B1, CYP11B2 ALDH1A1 1161/4885MEN1 1057/4885LMNA 1143/4885
US-20020151035-A1 D-aminoacylase and gene encoding the same NAALAD2, AANAT, DAO ALDH1A1 1209/4885MEN1 2048/4885LMNA 3964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.